Table 5.
Toxicity in feasibility phase
| Grade | ||||||
|---|---|---|---|---|---|---|
| Adverse Effect | 0 | 1 | 2 | 3 | 4 | Total |
| Leukopenia | 1 | 0 | 7 | 11 | 1 | 20 |
| Thrombocytopenia | 1 | 2 | 1 | 16 | 0 | 20 |
| Neutropenia | 0 | 0 | 0 | 1 | 19 | 20 |
| Anemia | 0 | 3 | 14 | 3 | 0 | 20 |
| Allergy | 19 | 1 | 0 | 0 | 0 | 20 |
| Cardiovascular | 17 | 2 | 0 | 1 | 0 | 20 |
| Constitutional | 3 | 14 | 2 | 1 | 0 | 20 |
| Dermatologic | 8 | 7 | 4 | 1 | 0 | 20 |
| Gastrointestinal | 3 | 8 | 8 | 1 | 0 | 20 |
| Genitourinary/Renal | 19 | 1 | 0 | 0 | 0 | 20 |
| Hemorrhage | 18 | 1 | 0 | 1 | 0 | 20 |
| Hepatic | 11 | 8 | 1 | 0 | 0 | 20 |
| Infection | 19 | 0 | 0 | 1 | 0 | 20 |
| Metabolic | 11 | 5 | 2 | 2 | 0 | 20 |
| Neuropathy-sensory | 5 | 11 | 3 | 1 | 0 | 20 |